Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Cordlife Group ( (SG:P8A) ).
Cordlife Group Limited has been granted an extension by Singapore’s Ministry of Health to submit written representations regarding the potential suspension of its cord blood banking service license. The company has halted the collection, testing, processing, and storage of new cord blood units since the notice from the Ministry, reflecting its proactive stance in addressing regulatory concerns.
More about Cordlife Group
Cordlife Group Limited, registered in Singapore, operates in the healthcare industry with a focus on cord blood banking and human tissue banking services.
YTD Price Performance: 16.00%
Average Trading Volume: 51,984
Technical Sentiment Signal: Strong Sell
Current Market Cap: S$44.42M
Learn more about P8A stock on TipRanks’ Stock Analysis page.